In this section we publish information about partners, clients and members of Farmavita.Net Network
You are kindly invited to Register and publish your professional or company profile.
|
Agency for medical promotion and medical information in Tunis
We take the honour & pleasure in introducing ourselves ,
Our company ( APROMED ) is specialising in medical promotion and medical Information within the Pharmaceutical area, we are dedicated to providing marketing, sales solutions to our wide range of clients around the country.
|
|
Read more...
|
|
SunMax Biotechnology Company
Medical Grade Porcine Collagen - SunMax Biotechnology Company LTD is a Taiwan manufacturer of medical grade porcine collagen and related biomedical products. We develop all of our products to strict quality control procedures that have been certified by a number authorities.
|
|
|
Primary and secondary packaging of drug products including EU batch release.
|
|
American Peptide Company, Inc. (APC)
American Peptide Company, Inc. (APC) offers comprehensive selections of pre-manufactured catalog peptides in convenient aliquots, a complete spectrum of non-GMP custom synthesis services from array screens to mg and kg of research-grade peptides, and full scale cGMP manufacturing of pharmaceutical-grade peptides for clinical studies. Our large-scale cGMP peptide manufacturing plant is located in Vista, California. As a wholly-owned subsidiary of ILS, Inc., a member of Otsuka Group, Otsuka Chemical, Co, Ltd. of Japan with offices in the USA, and presences in Japan, south Korea, England and China, APC remains dedicated to delivering high quality peptides to pharmaceutical and biotech companies worldwide.
|
|
Read more...
|
|
|
Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalisation and biotechnology.
The Company has a market capitalisation of over US$ 1 billion and an annual turnover of US$ 650 million. Wockhardt’s pace of growth and momentum permeates every mindset, system and technology within the organisation.
Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with more than 65% of its revenue coming from Europe and the United States. Wockhardt’s market presence covers formulations (respiratory, antibacterial, orthopaedic,dermatology, neurology, metabolic, pain management etc) biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).
|
|
Biopolymer Lda Portugal
The biopolymer Portugal is a Portuguese company whose main focus of the hospital market Medecine Urology and aesthetics.
Being a young and dynamic company seeks partnerships and new products in the OTC area.
|
|
Indoco Remedies Ltd.
Indoco Remedies Ltd., Mumbai, India, a research based organization is one of the fastest growing pharmaceutical companies in the country. With over four decades of existence in the domestic (Indian) market, catering to six major therapeutic segments, Indoco has an attractive record of successful product launches and brand build ups. The organization with its strengths in Research and Development (Finished Dosage Forms and API) backed by state-of-the-art manufacturing facilities, offers end to end solution to companies marketing generics in regulated zones.
|
|
Read more...
|
|
Jacobsen Pharma A/S
Regulatory affairs specialists in Scandinavia and EU. We offer support on applications for marketing authorisation (national, MRP, DCP), readability testing of Patient Information Leaflets, pharmacovigilance, eCTD, variation and renewal applications, medical translations and more.
|
|
Read more...
|
|
|
Personalized oncology company
GLG Pharma isan early stage, personalized oncology company that is developing a series ofanti-cancer compounds that, we believe, are the next generation of targetedtherapies.
Our compounds are all STAT3inhibitors. They are small molecules, have different chemical structures andact on different sites within the JAK-STAT3signaling pathway.
One compound (GLG-101)is in preclinical development by the National Cancer Institute RAID program.The NCI will complete the totalpreclinical package and we will file the INDfor GLG-101.
We want to file as soon as possible an exploratory IND for GLG-302 and initiate a Phase 0 clinical trial andthen proceed with the other compounds as fast as possible.
At this time, we are looking for a development partner.
Please let me know if this is of interest to you.
Thanks,
Hector J Gomez, MD, PhD
|
|
|
<< Start < Prev 1 2 3 4 5 6 Next > End >>
|
| Results 71 - 79 of 79 |